China's Mindray Sees Growth In Emerging Markets, But Looks To Jump-start Stagnant Sales At Home
This article was originally published in PharmAsia News
SHANGHAI - China's leading medical device company Mindray's third quarter report disappointed investors again with an 11.3% increase in revenue over the same period last year to $168 million, which missed Street expectations of $170-178 million. Weak sales in China are the culprit for slow growth, even as the company sees significant gains in other emerging markets
You may also be interested in...
China’s leading medical device company enters the orthopedic market with a $35.5 million acquisition of domestic player Dragonbio.
Mindray expects to hold its own amidst foreign competition, including in the high-end device market thanks to acquisitions and R&D investments that have boosted its technological capability.
Facing Tougher Competition At Home, China's Mindray Should Target Global Mid- To High-end Market, Analysts Say
Facing a new round of marketing campaigns from international device makers targeting China's low- to mid-end hospital markets, Shenzhen based Mindray Medical will be better off focusing instead on mid- to high-end global markets to stay competitive, analysts say